DBV TECHNOLOGIE/S (NASDAQ:DBVT) Downgraded to Sell at BidaskClub

Share on StockTwits

BidaskClub lowered shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a hold rating to a sell rating in a report issued on Friday morning, BidAskClub reports.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research raised DBV TECHNOLOGIE/S from a hold rating to a buy rating and set a $10.00 price target for the company in a report on Wednesday, April 10th. JMP Securities reissued a buy rating and set a $20.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Finally, Stifel Nicolaus reissued a hold rating and set a $10.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. DBV TECHNOLOGIE/S presently has an average rating of Hold and an average target price of $14.67.

NASDAQ:DBVT opened at $8.15 on Friday. DBV TECHNOLOGIE/S has a one year low of $3.60 and a one year high of $25.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34. The firm has a market capitalization of $484.34 million, a PE ratio of -2.40 and a beta of 1.98. The firm has a 50 day moving average of $9.13.

Hedge funds have recently bought and sold shares of the business. First Midwest Bank Trust Division increased its stake in DBV TECHNOLOGIE/S by 14.5% during the first quarter. First Midwest Bank Trust Division now owns 1,131,884 shares of the company’s stock worth $8,727,000 after acquiring an additional 142,993 shares during the last quarter. OLD Mission Capital LLC increased its stake in DBV TECHNOLOGIE/S by 1,278.6% during the fourth quarter. OLD Mission Capital LLC now owns 143,338 shares of the company’s stock worth $920,000 after acquiring an additional 132,941 shares during the last quarter. Exane Asset Management increased its stake in DBV TECHNOLOGIE/S by 46.4% during the first quarter. Exane Asset Management now owns 205,000 shares of the company’s stock worth $1,581,000 after acquiring an additional 65,000 shares during the last quarter. Bailard Inc. acquired a new stake in DBV TECHNOLOGIE/S during the first quarter worth $2,675,000. Finally, Bank of New York Mellon Corp increased its stake in DBV TECHNOLOGIE/S by 334.1% during the fourth quarter. Bank of New York Mellon Corp now owns 1,645,000 shares of the company’s stock worth $10,561,000 after acquiring an additional 1,266,041 shares during the last quarter. 46.56% of the stock is owned by institutional investors.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Featured Story: What is a conference call?

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastic  Rating Lowered to Sell at Zacks Investment Research
Elastic Rating Lowered to Sell at Zacks Investment Research
Diplomat Pharmacy  Stock Rating Lowered by Zacks Investment Research
Diplomat Pharmacy Stock Rating Lowered by Zacks Investment Research
Dicerna Pharmaceuticals  Rating Lowered to Sell at Zacks Investment Research
Dicerna Pharmaceuticals Rating Lowered to Sell at Zacks Investment Research
Eastgroup Properties  Rating Lowered to Hold at Zacks Investment Research
Eastgroup Properties Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research Upgrades NOW  to “Buy”
Zacks Investment Research Upgrades NOW to “Buy”
Zacks Investment Research Downgrades Endologix  to Hold
Zacks Investment Research Downgrades Endologix to Hold


© 2006-2019 Ticker Report